Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet 2022 Mar 31. pii: S0140-6736(22)00562.
PMID: 35367007